Piramal Pharma Solutions Acquires Solid Oral Dosage Drug Product Manufacturing Facility

Published on: 

The facility has dedicated manufacturing and packaging for oral solid dosage forms, liquids, creams, and ointments.

Piramal Pharma Solutions (PPS), a contract development and manufacturing organization, announced on June 20, 2020 that it has entered into an agreement with G&W Laboratories to acquire its solid oral dosage drug product manufacturing facility in Sellersville, PA.

The 221,000-ft2 facility has dedicated manufacturing and packaging technologies for oral solid dosage forms, liquids, creams, and ointments; quality control and microbiology labs; preformulation and analytical development infrastructure, with a pilot lab for research and development; and a temperature-controlled warehouse, according to a company press release. PPS plans to introduce the site to high potency drug manufacturing along with support development services and COVID-19 management drug opportunities.

“Many of our customers are looking for US-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them … and adds solid oral dosage capability in the US. We now offer solid oral drug product development and commercial manufacturing in all our major geographies, addressing a previously unmet customer need and strengthening our ability to work globally with customers to reduce the burden of disease on patients,” said Peter DeYoung, CEO, Piramal Pharma Solutions, in the press release.


Source: PPS